This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Puma Biotechnology, Takeda Oncology, and TESARO, Inc.
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
Edward Li, PharmD, MPH, BCOP
University of New England College of Pharmacy
Get updated on the latest drug treatments for solid tumors and the clinical trial data behind their FDA approvals. And importantly, learn how to spot the common adverse side effects from these newly approved treatments and how to help patients manage them.
These activities, certified for CME/CE/CPE credit, are jointly provided by